Jefferies Global Healthcare Conference
Logotype for Exelixis Inc

Exelixis (EXEL) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Exelixis Inc

Jefferies Global Healthcare Conference summary

18 Nov, 2026

Strategic transition and execution

  • Transitioning from a CABO-centered business toward multiple products and franchises, with Zanza development, commercial execution, early pipeline progress and disciplined expense management as priorities.

  • Long-term goal: build a business with multiple products and labels across RCC, NET and CRC, extending the franchise-building approach used with CABO.

  • CABO revenue and the planned Zanza launch support investment across internal R&D, external opportunities and share buybacks; these priorities are not viewed as mutually exclusive.

Capital allocation and R&D priorities

  • Annual R&D budget targeted at a cap of ~ $1B; plan is to keep expenses flat as revenue grows, supporting earnings growth and investment flexibility.

  • Programs are prioritized by evidence, biology, vision and commercial opportunity; franchises are assessed for potential to lead across multiple products and indications.

  • Financial flexibility also leaves room to pursue external opportunities when attractive, while maintaining deliberate expense management.

Zanza development and differentiation

  • Zanza was designed to retain CABO-like kinase activity while using a shorter half-life to make dose holds, reductions and symptom resolution more manageable, particularly in combination regimens.

  • Differing tissue distribution may reduce hand-foot syndrome burden; the profile supports evaluating activity and combinations across tumor types in wave one and wave two.

  • Seven pivotal studies are underway; management said randomized survival trials are needed to determine whether early efficacy signals translate into survival benefit.

  • Zanza studies are designed individually around dose, combination and patient population; efficacy, safety and secondary endpoints all influence commercial adoption.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Exelixis